A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers

NCT ID: NCT02750280

Last Updated: 2016-04-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2015-12-31

Brief Summary

This ia a prospective controlled longitudinal study to evaluate the effects of MatriStem® plus standard local wound care versus standard local wound care alone in the treatment of diabetic foot ulcers (DFUs), as assessed by incidence of complete wound healing by 16 weeks and ulcer recurrence with a 2 year follow-up.

Conditions

Neuropathic Diabetic Foot Ulcer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Urinary Bladder matrix (UBM)

UBM covered with silicone foam dressing plus total contact cast

Group Type: EXPERIMENTAL

MatriStem® [Urinary Bladder Matrix (UBM)]

Intervention Type: DEVICE

Porcine derived urinary bladder extracellular matrix

Standard Care

Silicone foam dressing plus total contact cast

Group Type: ACTIVE_COMPARATOR

Mepilex® [Silicone foam dressing]

Intervention Type: DEVICE

primary wound dressing

Interventions

MatriStem® [Urinary Bladder Matrix (UBM)]

Porcine derived urinary bladder extracellular matrix

Intervention Type: DEVICE

Mepilex® [Silicone foam dressing]

primary wound dressing

Intervention Type: DEVICE

Other Intervention Names

MatriStem; Mepilex

Eligibility Criteria

Inclusion Criteria

1. Male and female subjects 18-85 years of age with diabetes mellitus (type 1 or type 2)

2. Subject's foot ulcer is on the plantar surface of the foot.

3. DFU has not healed after more than2 months of SOC treatment administered

4. Subject's ulcer must be Wagner type 1 or 2 (uninfected, extending through the dermis and into subcutaneous tissue or granulating but without exposure of tendon, bone, or joint capsule.

5. Subject's wound is free of necrotic debris (post debridement) and clinical infection, should be comprised of healthy, vascular tissue.

6. Subject's Ankle-Brachial Index (ABI) by Doppler method is ≥ 0.7

7. The subject has adequate circulation to the foot to allow for healing. This must be demonstrated by methods described in section 5.1

8. Subject's diabetes is under control as determined by the Investigator

9. Study subject must be reliable, responsible and able to visit the clinic weekly for the full 16 week period. The subject is willing and able to tolerate TCC. Subject is willing to comply with the monthly follow-up regimen for 32 weeks (8 months) The subject is able to return to the clinic if ulcer recurrence occurs

10. Subject or his/her legal representative has read and signed the Institutional Review Board (IRB) approved Informed Consent form before treatment

11. No active malignancy except non-melanoma skin cancer

Exclusion Criteria

1. Subject has clinical evidence of gangrene on any part of the affected foot

2. Subject has a Wagner type 3 or greater ulceration

3. The subject's ulcer is due to a non-diabetic etiology, Ulcers of arterial, venous stasis, pressure, radiation, traumatic, rheumatoid, vasculitis, collagen vascular disease, or other non-diabetic etiologies

4. Subject has a known sensitivity to bovine or porcine derived devices

5. Subject has one or more medical condition(s) including renal, hepatic, hematological, neurologic, or immune disease that in the opinion of the Investigator would make the subject an inappropriate candidate for this wound healing study

6. Subject has or has had a malignant disease (other than cutaneous epithelioma) not in remission

7. Subject is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents, or is anticipated to require such agents during the course of the study

8. Subject has chronic osteomyelitis as determined by high resolution ultrasonography

9. Subject's ulcer is infected or accompanied by active cellulitis as determined by the Investigator

10. Subject has any condition(s) that seriously compromises the subject's ability to complete the study

11. Subject is pregnant or lactating at the time of treatment

12. Subject has received growth factor therapy (e.g. autologous platelet-rich plasma gel, bacaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of enrollment. If Santyl or any other collagenase is used, a subject must have a washout period of 2 weeks before MatriStem® can be applied.

13. Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization

14. Subject has a history of alcohol or drug abuse

15. Subject allergic to a broad spectrum of primary & secondary dressing materials, including occlusive dressings and the adhesives on such dressings.

16. Subject is currently enrolled or participated within the previous 30 days of enrollment in another device, drug or biological trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Integra LifeSciences Corporation

INDUSTRY

Sponsor Role: collaborator

Calvary Hospital, Bronx, NY

OTHER

Sponsor Role: lead

Responsible Party

Oscar M. Alvarez, PhD

Director, Center for Curative & palliative Wound Care

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

oscar Alvarez, PhD

Role: PRINCIPAL_INVESTIGATOR

Calvary Hospital Director, Center for curative and palliative wound care

Locations

Calvary Hospital Center for Curative and Palliative Wound Care

The Bronx, New York, United States

Countries

United States

Other Identifiers

CA2014-002

Identifier Type: -

Identifier Source: org_study_id